Dana-Farber Cancer Institute Inc

📅 Upcoming

🕒 Recent(90d)

News

• Rare EGFR mutation increases lung cancer risk 62 times in never smokers
  A rare inherited germline mutation was found to increase risk for lung cancer by 25 times, while smoking only increased risk by 4 times.
  fiercebiotech · 13d ago
• STAT+: Top Boston hospitals clash over Medicare Advantage network after split
  First, Mass General Brigham split with Dana-Farber. Now its Medicare Advantage plan is dropping the cancer hospital.
  stat · 26d ago
• STAT+: As young people increasingly get cancer, new fertility options are changing their futures
  New technologies, cancer doctors, and reproductive specialists are working to give more patients a chance to have children post-treatment.
  stat · 1mo ago
• #ASCO26: Personalized cancer vaccines may help brain cancer patients live longer
  Personalized cancer vaccines might make notoriously deadly brain cancers more susceptible to immunotherapy and possibly prolong survival for some patients, according to new research from the Dana-F…
  endpoints · 4mo ago
• Bristol Myers unveils data for one of its next-gen blood cancer drugs
  Called mezigdomide, the drug is one of two protein-degrading medicines Bristol Myers hopes to soon position as successors to its lucrative Revlimid franchise.
  biopharma_dive · 4mo ago
• Dana-Farber Study Finds Stage IV Breast Cancer Increasing in Incidence and Proportion Over the Last Decade
  A Dana-Farber study showed cases of stage IV breast cancer are increasing in incidence and as a proportion of all breast cancer diagnoses.
  onclive · 4mo ago
• GU Cancer Experts Highlight Top Abstracts to Watch During ASCO 2026
  We spoke with leading voices in GU oncology to see which presentations they are most looking forward to during the 2026 ASCO Annual Meeting.
  onclive · 4mo ago
• Post–T-DXd Sacituzumab Govitecan Plus Trastuzumab Yields Low ORR in HER2+ Metastatic Breast Cancer
  Sacituzumab govitecan plus trastuzumab following T-DXd did not meet the primary end point of the SATEEN trial in HER2+ metastatic breast cancer.
  onclive · 4mo ago
• Giants of Cancer Care Announces the 14th Annual Class of Inductees
  onclive · 4mo ago
• Dr McGregor on the DAD-IO Trial of Sacituzumab Govitecan and EV in Metastatic Urothelial Carcinoma
  Bradley McGregor, MD, discusses the background and design of the phase 1/2 DAD-IO trial in metastatic urothelial carcinoma.
  onclive · 4mo ago